10 XP 0   0   5  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

LGDN (Ligand) Stock Analysis
Buy, Hold or Sell?

Let's analyze Ligand together

I guess you are interested in Ligand Pharmaceuticals Incorporated. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Ligand’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Ligand’s Price Targets

I'm going to help you getting a better view of Ligand Pharmaceuticals Incorporated. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Ligand Pharmaceuticals Incorporated

I send you an email if I find something interesting about Ligand Pharmaceuticals Incorporated.

1. Quick Overview

1.1. Quick analysis of Ligand (30 sec.)










1.2. What can you expect buying and holding a share of Ligand? (30 sec.)

How much money do you get?

How much money do you get?
€0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
€36.47
Expected worth in 1 year
€38.82
How sure are you?
68.6%

+ What do you gain per year?

Total Gains per Share
€2.35
Return On Investment
1.5%

For what price can you sell your share?

Current Price per Share
€160.00
Expected price per share
€151.00 - €
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Ligand (5 min.)




Live pricePrice per Share (EOD)
€160.00
Intrinsic Value Per Share
€35.32 - €41.72
Total Value Per Share
€71.79 - €78.19

2.2. Growth of Ligand (5 min.)




Is Ligand growing?

Current yearPrevious yearGrowGrow %
How rich?$828.6m$737.7m$86.2m10.5%

How much money is Ligand making?

Current yearPrevious yearGrowGrow %
Making money-$18.9m$10.5m-$29.5m-155.6%
Net Profit Margin-42.5%46.6%--

How much money comes from the company's main activities?

2.3. Financial Health of Ligand (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#76 / 852

Most Revenue
#156 / 852

Most Profit
#628 / 852

Most Efficient
#390 / 852
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Ligand?

Welcome investor! Ligand's management wants to use your money to grow the business. In return you get a share of Ligand.

First you should know what it really means to hold a share of Ligand. And how you can make/lose money.

Speculation

The Price per Share of Ligand is €160.00. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Ligand.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Ligand, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €36.47. Based on the TTM, the Book Value Change Per Share is €0.59 per quarter. Based on the YOY, the Book Value Change Per Share is €1.21 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Ligand.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 β‚¬% of Price per Share€% of Price per Share€% of Price per Share€% of Price per Share€% of Price per Share€% of Price per Share
Usd Eps0.250.2%-0.97-0.6%0.540.3%-0.20-0.1%-0.020.0%1.130.7%
Usd Book Value Change Per Share1.691.1%0.680.4%1.410.9%0.110.1%0.340.2%1.210.8%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share1.691.1%0.680.4%1.410.9%0.110.1%0.340.2%1.210.8%
Usd Price Per Share111.89-112.33-77.07-90.77-104.43-118.10-
Price to Earnings Ratio112.49-2.85--3.86-129.53-47.78-24.88-
Price-to-Total Gains Ratio66.10--47.02-108.45-41.39-101.87-62.28-
Price to Book Ratio2.63-2.66-2.04-2.35-2.67-3.53-
Price-to-Total Gains Ratio66.10--47.02-108.45-41.39-101.87-62.28-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share186.48
Number of shares5
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.680.34
Usd Total Gains Per Share0.680.34
Gains per Quarter (5 shares)3.421.71
Gains per Year (5 shares)13.686.85
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1014407-3
2027180144
30413202111
40554602718
50686003425
60827404132
70968804839
8010910205546
9012311606253
10013713006960

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%6.06.00.050.0%10.010.00.050.0%18.017.00.051.4%18.017.00.051.4%
Book Value Change Per Share2.02.00.050.0%8.04.00.066.7%15.05.00.075.0%24.011.00.068.6%24.011.00.068.6%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.035.00.0%0.00.035.00.0%
Total Gains per Share2.02.00.050.0%8.04.00.066.7%15.05.00.075.0%24.011.00.068.6%24.011.00.068.6%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Ligand Pharmaceuticals Incorporated compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--1.4520.587+147%1.214+20%0.096+1413%0.294+394%1.042+39%
Book Value Per Share--36.47036.267+1%32.469+12%32.907+11%33.322+9%30.983+18%
Current Ratio--5.4528.037-32%16.956-68%9.750-44%9.283-41%11.358-52%
Debt To Asset Ratio--0.1270.121+4%0.116+9%0.143-11%0.235-46%0.327-61%
Debt To Equity Ratio--0.1450.138+5%0.131+10%0.170-15%0.348-58%0.589-75%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--1768438138.5001781176282.775-1%1206228551.050+47%1411132774.392+25%1521611395.952+16%1629155592.190+9%
Eps--0.213-0.835+491%0.464-54%-0.170+179%-0.014+107%0.973-78%
Ev To Sales Ratio--10.81811.172-3%10.641+2%10.116+7%9.368+15%11.013-2%
Free Cash Flow Per Share--0.6860.420+63%-0.090+113%0.472+45%0.572+20%0.603+14%
Free Cash Flow To Equity Per Share--1.3461.363-1%0.243+454%0.002+59568%-0.588+144%-1.010+175%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--41.722----------
Intrinsic Value_10Y_min--35.316----------
Intrinsic Value_1Y_max--2.224----------
Intrinsic Value_1Y_min--2.183----------
Intrinsic Value_3Y_max--8.173----------
Intrinsic Value_3Y_min--7.773----------
Intrinsic Value_5Y_max--15.921----------
Intrinsic Value_5Y_min--14.649----------
Market Cap3119124160.000+40%1871474496.0001878784943.2500%1289075531.750+45%1518298666.633+23%1746748518.652+7%1975400928.079-5%
Net Profit Margin--0.102-0.425+517%0.466-78%0.072+41%0.064+60%0.507-80%
Operating Margin----0%-0%-0.0390%0.010-100%0.712-100%
Operating Ratio--0.8571.159-26%1.036-17%1.143-25%1.118-23%0.969-12%
Pb Ratio4.387+40%2.6322.660-1%2.036+29%2.354+12%2.671-1%3.525-25%
Pe Ratio187.483+40%112.4902.854+3842%-3.861+103%129.532-13%47.783+135%24.878+352%
Price Per Share160.000+40%96.00096.3750%66.125+45%77.883+23%89.602+7%101.331-5%
Price To Free Cash Flow Ratio58.308+40%34.98514.519+141%24.733+41%-93.857+368%-46.166+232%-25.073+172%
Price To Total Gains Ratio110.166+40%66.099-47.016+171%108.451-39%41.394+60%101.869-35%62.276+6%
Quick Ratio--3.5365.152-31%13.350-74%7.258-51%6.859-48%9.104-61%
Return On Assets--0.005-0.021+503%0.011-54%-0.001+110%0.001+335%0.013-61%
Return On Equity--0.006-0.023+499%0.013-54%0.000+105%0.002+140%0.025-77%
Total Gains Per Share--1.4520.587+147%1.214+20%0.096+1413%0.294+394%1.042+39%
Usd Book Value--828624736.526824015203.956+1%737717233.378+12%747686385.180+11%757095372.263+9%703971963.134+18%
Usd Book Value Change Per Share--1.6930.684+147%1.415+20%0.112+1413%0.343+394%1.214+39%
Usd Book Value Per Share--42.50642.269+1%37.842+12%38.354+11%38.836+9%36.111+18%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--2061114650.4222075960957.574-1%1405859376.249+47%1644675248.553+25%1773438081.982+16%1898780842.698+9%
Usd Eps--0.249-0.973+491%0.541-54%-0.198+179%-0.016+107%1.134-78%
Usd Free Cash Flow--15586800.8479539352.145+63%-2040735.780+113%10729656.335+45%13002902.312+20%8610480.540+81%
Usd Free Cash Flow Per Share--0.8000.489+63%-0.105+113%0.550+45%0.667+20%0.703+14%
Usd Free Cash Flow To Equity Per Share--1.5691.589-1%0.283+454%0.003+59568%-0.685+144%-1.178+175%
Usd Market Cap3635339208.480+40%2181203525.0882189723851.3580%1502417532.255+45%1769577095.961+23%2035835398.489+7%2302329781.676-5%
Usd Price Per Share186.480+40%111.888112.3250%77.069+45%90.773+23%104.431+7%118.101-5%
Usd Profit--4847560.071-18968191.521+491%10536967.406-54%-546979.863+111%1690345.297+187%23254286.722-79%
Usd Revenue--47632503.30046901418.833+2%33373355.846+43%42327973.766+13%50003777.269-5%46450023.823+3%
Usd Total Gains Per Share--1.6930.684+147%1.415+20%0.112+1413%0.343+394%1.214+39%
 EOD+4 -4MRQTTM+21 -14YOY+20 -153Y+30 -55Y+28 -810Y+21 -15

3.3 Fundamental Score

Let's check the fundamental score of Ligand Pharmaceuticals Incorporated based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15187.483
Price to Book Ratio (EOD)Between0-14.387
Net Profit Margin (MRQ)Greater than00.102
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than13.536
Current Ratio (MRQ)Greater than15.452
Debt to Asset Ratio (MRQ)Less than10.127
Debt to Equity Ratio (MRQ)Less than10.145
Return on Equity (MRQ)Greater than0.150.006
Return on Assets (MRQ)Greater than0.050.005
Total5/10 (50.0%)

3.4 Technical Score

Let's check the technical score of Ligand Pharmaceuticals Incorporated based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5070.361
Ma 20Greater thanMa 50154.000
Ma 50Greater thanMa 100144.400
Ma 100Greater thanMa 200126.045
OpenGreater thanClose162.000
Total5/5 (100.0%)

4. In-depth Analysis

4.1 About Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI, a dual endothelin and angiotensin II receptor antagonist for immunoglobulin A nephropathy; Ohtuvayre for respiratory disease; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; LYTENAVA to treat Opthamology; MEKINIST for cardiology; MINNEBRO for metabolic disease; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, JZP341, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; CE-furosemide for cardiology; CE-Meloxicam for neurology; V117, CX2101A, and Sitavig for infectious disease; REV-0100, OPT-302, and Reproxalap for opthamology; Vilazodone and Topiramate Injection for CNS; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.

Fundamental data was last updated by Penke on 2025-10-13 13:55:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is cheap.
Based on how much money comes from the company's main activities, the company is cheap.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Ligand earns for each €1 of revenue.

  • Above 10% is considered healthy but always compareΒ Ligand to theΒ Biotechnology industry mean.
  • A Net Profit Margin of 10.2%Β means thatΒ €0.10 for each €1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Ligand Pharmaceuticals Incorporated:

  • The MRQ is 10.2%. The company is making a huge profit. +2
  • The TTM is -42.5%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ10.2%TTM-42.5%+52.7%
TTM-42.5%YOY46.6%-89.1%
TTM-42.5%5Y6.4%-48.8%
5Y6.4%10Y50.7%-44.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ10.2%-74.7%+84.9%
TTM-42.5%-164.2%+121.7%
YOY46.6%-181.7%+228.3%
3Y7.2%-262.6%+269.8%
5Y6.4%-340.9%+347.3%
10Y50.7%-472.3%+523.0%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Ligand is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Ligand to theΒ Biotechnology industry mean.
  • 0.5% Return on Assets means thatΒ Ligand generatedΒ €0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Ligand Pharmaceuticals Incorporated:

  • The MRQ is 0.5%. Using its assets, the company is inefficient in making profit. -1
  • The TTM is -2.1%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ0.5%TTM-2.1%+2.6%
TTM-2.1%YOY1.1%-3.2%
TTM-2.1%5Y0.1%-2.2%
5Y0.1%10Y1.3%-1.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5%-11.9%+12.4%
TTM-2.1%-11.6%+9.5%
YOY1.1%-10.8%+11.9%
3Y-0.1%-12.0%+11.9%
5Y0.1%-11.7%+11.8%
10Y1.3%-13.8%+15.1%
4.3.1.3. Return on Equity

Shows how efficient Ligand is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Ligand to theΒ Biotechnology industry mean.
  • 0.6% Return on Equity means Ligand generated €0.01Β for eachΒ €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Ligand Pharmaceuticals Incorporated:

  • The MRQ is 0.6%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is -2.3%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ0.6%TTM-2.3%+2.9%
TTM-2.3%YOY1.3%-3.6%
TTM-2.3%5Y0.2%-2.6%
5Y0.2%10Y2.5%-2.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6%-14.1%+14.7%
TTM-2.3%-14.7%+12.4%
YOY1.3%-15.0%+16.3%
3Y0.0%-16.5%+16.5%
5Y0.2%-16.8%+17.0%
10Y2.5%-19.5%+22.0%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Ligand Pharmaceuticals Incorporated.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Ligand is operatingΒ .

  • Measures how much profit Ligand makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Ligand to theΒ Biotechnology industry mean.
  • An Operating Margin of 0.0%Β means the company generated €0.00 Β for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Ligand Pharmaceuticals Incorporated:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y1.0%-1.0%
5Y1.0%10Y71.2%-70.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--155.0%+155.0%
TTM--266.6%+266.6%
YOY--242.6%+242.6%
3Y-3.9%-247.4%+243.5%
5Y1.0%-332.9%+333.9%
10Y71.2%-499.9%+571.1%
4.3.2.2. Operating Ratio

Measures how efficient Ligand is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 0.86 means that the operating costs are €0.86 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Ligand Pharmaceuticals Incorporated:

  • The MRQ is 0.857. The company is less efficient in keeping operating costs low.
  • The TTM is 1.159. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ0.857TTM1.159-0.302
TTM1.159YOY1.036+0.123
TTM1.1595Y1.118+0.041
5Y1.11810Y0.969+0.150
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8571.877-1.020
TTM1.1592.741-1.582
YOY1.0362.783-1.747
3Y1.1433.562-2.419
5Y1.1184.630-3.512
10Y0.9696.180-5.211
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Ligand Pharmaceuticals Incorporated.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Ligand is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 5.45Β means the company has €5.45 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Ligand Pharmaceuticals Incorporated:

  • The MRQ is 5.452. The company is very able to pay all its short-term debts. +2
  • The TTM is 8.037. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ5.452TTM8.037-2.584
TTM8.037YOY16.956-8.919
TTM8.0375Y9.283-1.247
5Y9.28310Y11.358-2.075
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.4523.345+2.107
TTM8.0373.584+4.453
YOY16.9564.032+12.924
3Y9.7504.408+5.342
5Y9.2835.706+3.577
10Y11.3586.080+5.278
4.4.3.2. Quick Ratio

Measures if Ligand is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Ligand to theΒ Biotechnology industry mean.
  • A Quick Ratio of 3.54Β means the company can pay off €3.54 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Ligand Pharmaceuticals Incorporated:

  • The MRQ is 3.536. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 5.152. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ3.536TTM5.152-1.615
TTM5.152YOY13.350-8.198
TTM5.1525Y6.859-1.708
5Y6.85910Y9.104-2.245
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.5362.898+0.638
TTM5.1523.142+2.010
YOY13.3503.790+9.560
3Y7.2584.369+2.889
5Y6.8595.692+1.167
10Y9.1046.457+2.647
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Ligand Pharmaceuticals Incorporated.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of LigandΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Ligand to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.13Β means that Ligand assets areΒ financed with 12.7% credit (debt) and the remaining percentage (100% - 12.7%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Ligand Pharmaceuticals Incorporated:

  • The MRQ is 0.127. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.121. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.127TTM0.121+0.005
TTM0.121YOY0.116+0.005
TTM0.1215Y0.235-0.114
5Y0.23510Y0.327-0.092
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1270.344-0.217
TTM0.1210.361-0.240
YOY0.1160.333-0.217
3Y0.1430.346-0.203
5Y0.2350.348-0.113
10Y0.3270.378-0.051
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Ligand is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Ligand to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 14.5% means that company has €0.14 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Ligand Pharmaceuticals Incorporated:

  • The MRQ is 0.145. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.138. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.145TTM0.138+0.007
TTM0.138YOY0.131+0.007
TTM0.1385Y0.348-0.210
5Y0.34810Y0.589-0.241
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1450.400-0.255
TTM0.1380.439-0.301
YOY0.1310.432-0.301
3Y0.1700.471-0.301
5Y0.3480.471-0.123
10Y0.5890.518+0.071
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every €1 in earnings Ligand generates.

  • Above 15 is considered overpriced butΒ always compareΒ Ligand to theΒ Biotechnology industry mean.
  • A PE ratio of 112.49 means the investor is paying €112.49Β for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Ligand Pharmaceuticals Incorporated:

  • The EOD is 187.483. Based on the earnings, the company is expensive. -2
  • The MRQ is 112.490. Based on the earnings, the company is expensive. -2
  • The TTM is 2.854. Based on the earnings, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD187.483MRQ112.490+74.993
MRQ112.490TTM2.854+109.636
TTM2.854YOY-3.861+6.715
TTM2.8545Y47.783-44.929
5Y47.78310Y24.878+22.905
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD187.483-2.900+190.383
MRQ112.490-2.330+114.820
TTM2.854-2.701+5.555
YOY-3.861-3.622-0.239
3Y129.532-3.859+133.391
5Y47.783-5.965+53.748
10Y24.878-6.960+31.838
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Ligand Pharmaceuticals Incorporated:

  • The EOD is 58.308. Based on how much money comes from the company's main activities, the company is overpriced. -1
  • The MRQ is 34.985. Based on how much money comes from the company's main activities, the company is fair priced.
  • The TTM is 14.519. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD58.308MRQ34.985+23.323
MRQ34.985TTM14.519+20.466
TTM14.519YOY24.733-10.215
TTM14.5195Y-46.166+60.684
5Y-46.16610Y-25.073-21.093
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD58.308-3.654+61.962
MRQ34.985-2.917+37.902
TTM14.519-3.869+18.388
YOY24.733-4.368+29.101
3Y-93.857-5.330-88.527
5Y-46.166-8.374-37.792
10Y-25.073-9.887-15.186
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Ligand is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of 2.63 means the investor is paying €2.63Β for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Ligand Pharmaceuticals Incorporated:

  • The EOD is 4.387. Based on the equity, the company is fair priced.
  • The MRQ is 2.632. Based on the equity, the company is underpriced. +1
  • The TTM is 2.660. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD4.387MRQ2.632+1.755
MRQ2.632TTM2.660-0.028
TTM2.660YOY2.036+0.624
TTM2.6605Y2.671-0.011
5Y2.67110Y3.525-0.854
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD4.3872.492+1.895
MRQ2.6322.062+0.570
TTM2.6602.235+0.425
YOY2.0362.486-0.450
3Y2.3542.682-0.328
5Y2.6713.814-1.143
10Y3.5254.508-0.983
4.6.2. Total Gains per Share

2.4. Latest News of Ligand Pharmaceuticals Incorporated

Does Ligand Pharmaceuticals Incorporated still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Ligand Pharmaceuticals Incorporated to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2025-10-08
19:38
3 Stocks That May Be Priced Below Intrinsic Value By Up To 44.4%Read
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2024-06-302024-09-302024-12-312025-03-312025-06-30
Income before Tax  -56,11150,672-5,439-28,198-33,638-9,422-43,05952,6909,630
Net Income  -44,54538,391-6,154-20,522-26,677-9,751-36,42740,5864,159
Total Other Income Expense Net -63,73148,371-15,360-20,624-35,98423,606-12,37813,266888
Net Income from Continuing Operations  -44,54538,391-6,154-20,522-26,677-9,751-36,42740,5864,159



6.2. Latest Balance Sheet

Balance Sheet of 2025-06-30. Currency in USD. All numbers in thousands.

Summary
Total Assets948,604
Total Liabilities120,075
Total Stockholder Equity828,529
 As reported
Total Liabilities 120,075
Total Stockholder Equity+ 828,529
Total Assets = 948,604

Assets

Total Assets948,604
Total Current Assets352,945
Long-term Assets595,659
Total Current Assets
Cash And Cash Equivalents 67,669
Short-term Investments 187,627
Net Receivables 41,288
Inventory 12,889
Other Current Assets 4,816
Total Current Assets  (as reported)352,945
Total Current Assets  (calculated)314,289
+/- 38,656
Long-term Assets
Property Plant Equipment 11,623
Goodwill 101,541
Long Term Investments 204,464
Intangible Assets 250,133
Long-term Assets Other 9,111
Long-term Assets  (as reported)595,659
Long-term Assets  (calculated)576,872
+/- 18,787

Liabilities & Shareholders' Equity

Total Current Liabilities64,734
Long-term Liabilities55,341
Total Stockholder Equity828,529
Total Current Liabilities
Accounts payable 8,584
Other Current Liabilities 37,157
Total Current Liabilities  (as reported)64,734
Total Current Liabilities  (calculated)45,741
+/- 18,993
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt5,742
Long-term Liabilities Other 18,466
Long-term Liabilities  (as reported)55,341
Long-term Liabilities  (calculated)24,208
+/- 31,133
Total Stockholder Equity
Retained Earnings 461,380
Total Stockholder Equity (as reported)828,529
Total Stockholder Equity (calculated)461,380
+/- 367,149
Other
Capital Stock20
Common Stock Shares Outstanding 19,411
Net Invested Capital 828,529
Net Working Capital 288,211
Property Plant and Equipment Gross 11,623



6.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-31
> Total Assets 
601,585
629,723
640,024
662,337
671,021
754,668
1,858,284
2,105,742
1,260,803
1,913,988
1,801,836
1,547,476
1,494,915
1,185,917
1,242,936
1,247,449
1,362,285
1,295,121
1,256,283
1,273,656
1,301,383
1,105,184
1,076,288
1,050,605
762,668
811,076
758,105
769,226
787,216
913,869
866,405
954,866
941,774
905,435
948,604
948,604905,435941,774954,866866,405913,869787,216769,226758,105811,076762,6681,050,6051,076,2881,105,1841,301,3831,273,6561,256,2831,295,1211,362,2851,247,4491,242,9361,185,9171,494,9151,547,4761,801,8361,913,9881,260,8032,105,7421,858,284754,668671,021662,337640,024629,723601,585
   > Total Current Assets 
163,053
174,701
197,177
224,201
237,021
349,051
1,480,470
1,745,225
870,540
1,567,895
1,442,307
1,183,103
1,123,645
830,727
863,624
857,741
500,559
437,428
410,901
432,082
464,751
276,066
243,784
220,432
263,601
328,195
276,711
253,994
237,429
368,913
312,259
309,388
331,559
309,316
352,945
352,945309,316331,559309,388312,259368,913237,429253,994276,711328,195263,601220,432243,784276,066464,751432,082410,901437,428500,559857,741863,624830,7271,123,6451,183,1031,442,3071,567,895870,5401,745,2251,480,470349,051237,021224,201197,177174,701163,053
       Cash And Cash Equivalents 
18,752
10,641
60,223
32,739
20,620
51,024
151,459
115,560
117,164
105,113
273,047
225,302
71,543
117,527
115,156
456,916
47,619
31,853
21,863
23,430
19,522
14,993
5,280
4,116
45,006
88,728
28,445
19,275
22,954
50,093
18,139
63,619
72,307
47,989
67,669
67,66947,98972,30763,61918,13950,09322,95419,27528,44588,72845,0064,1165,28014,99319,52223,43021,86331,85347,619456,916115,156117,52771,543225,302273,047105,113117,164115,560151,45951,02420,62032,73960,22310,64118,752
       Short-term Investments 
122,296
148,733
112,404
169,520
181,041
240,864
865,264
1,020,611
656,665
1,396,316
1,119,378
924,239
998,324
654,163
694,724
338,154
363,567
307,354
279,972
299,781
321,586
189,006
142,655
117,291
166,864
193,937
190,596
171,227
147,355
260,500
208,793
156,024
183,858
160,912
187,627
187,627160,912183,858156,024208,793260,500147,355171,227190,596193,937166,864117,291142,655189,006321,586299,781279,972307,354363,567338,154694,724654,163998,324924,2391,119,3781,396,316656,6651,020,611865,264240,864181,041169,520112,404148,733122,296
       Net Receivables 
17,907
7,057
16,669
15,823
29,970
40,985
42,001
46,976
55,850
26,615
20,259
21,958
41,748
46,777
44,553
32,907
59,064
55,581
62,850
70,714
91,646
41,797
63,272
65,953
35,038
29,188
27,994
36,003
32,917
28,435
37,481
34,318
38,376
38,492
41,288
41,28838,49238,37634,31837,48128,43532,91736,00327,99429,18835,03865,95363,27241,79791,64670,71462,85055,58159,06432,90744,55346,77741,74821,95820,25926,61555,85046,97642,00140,98529,97015,82316,6697,05717,907
       Inventory 
1,923
7,629
6,809
5,007
4,373
10,531
9,520
8,136
7,124
11,905
9,638
6,565
7,296
7,320
3,702
13,430
26,487
36,932
39,946
32,996
27,326
25,614
24,773
22,326
13,294
14,011
26,906
25,392
23,969
21,337
14,472
13,440
14,114
11,814
12,889
12,88911,81414,11413,44014,47221,33723,96925,39226,90614,01113,29422,32624,77325,61427,32632,99639,94636,93226,48713,4303,7027,3207,2966,5659,63811,9057,1248,1369,52010,5314,3735,0076,8097,6291,923
       Other Current Assets 
2,175
641
1,072
1,112
1,514
5,647
412,226
553,942
33,737
9,228
5,672
5,039
4,734
4,940
5,489
16,334
3,822
5,708
6,270
5,161
4,671
4,656
7,804
10,746
3,399
2,331
2,770
2,097
2,657
7,311
7,122
19,741
16,897
13,285
4,816
4,81613,28516,89719,7417,1227,3112,6572,0972,7702,3313,39910,7467,8044,6564,6715,1616,2705,7083,82216,3345,4894,9404,7345,0395,6729,22833,737553,942412,2265,6471,5141,1121,0726412,175
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
346,093
359,529
364,373
371,270
355,190
379,312
389,708
861,726
857,693
845,382
841,574
836,632
829,118
832,504
830,173
499,067
482,881
481,394
515,232
549,787
544,956
554,146
645,478
610,215
596,119
595,659
595,659596,119610,215645,478554,146544,956549,787515,232481,394482,881499,067830,173832,504829,118836,632841,574845,382857,693861,726389,708379,312355,190371,270364,373359,529346,093000000000
       Property Plant Equipment 
1,819
1,898
1,875
3,526
4,212
4,119
4,187
4,407
5,372
10,456
17,232
16,691
17,538
16,320
17,572
11,426
37,168
42,457
41,511
48,448
53,260
55,987
70,697
46,552
15,009
27,352
15,154
25,979
25,062
24,382
25,458
25,191
24,806
10,492
11,623
11,62310,49224,80625,19125,45824,38225,06225,97915,15427,35215,00946,55270,69755,98753,26048,44841,51142,45737,16811,42617,57216,32017,53816,69117,23210,4565,3724,4074,1874,1194,2123,5261,8751,8981,819
       Goodwill 
72,207
72,207
72,207
72,207
85,959
85,961
85,961
85,961
86,646
86,809
88,000
93,513
95,229
94,341
103,369
102,136
784,992
774,300
762,523
190,183
734,996
181,206
709,570
181,206
448,128
105,673
431,050
103,770
103,370
105,250
105,250
105,250
105,250
101,541
101,541
101,541101,541105,250105,250105,250105,250103,370103,770431,050105,673448,128181,206709,570181,206734,996190,183762,523774,300784,992102,136103,36994,34195,22993,51388,00086,80986,64685,96185,96185,96185,95972,20772,20772,20772,207
       Long Term Investments 
8,345
10,469
6,014
5,137
6,438
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,000
0
0
47,082
111,612
112,679
93,659
212,404
195,932
199,228
204,464
204,464199,228195,932212,40493,659112,679111,61247,082003,00000000000000000000006,4385,1376,01410,4698,345
       Intangible Assets 
230,526
227,620
222,246
220,299
248,110
245,275
242,438
237,210
251,253
247,313
252,617
251,681
230,538
216,901
225,901
235,416
10,979
10,451
10,638
573,120
10,110
549,828
10,267
527,218
10,182
344,347
10,783
321,445
299,606
291,420
283,162
274,905
266,648
258,391
250,133
250,133258,391266,648274,905283,162291,420299,606321,44510,783344,34710,182527,21810,267549,82810,110573,12010,63810,45110,979235,416225,901216,901230,538251,681252,617247,313251,253237,210242,438245,275248,110220,299222,246227,620230,526
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
6,396
1,680
2,488
2,357
1,270
6,059
13,704
18,701
19,949
20,456
3,095
23,252
6,442
37,270
6,279
17,218
4,634
15,877
8,426
6,392
11,225
11,922
8,404
6,924
7,892
9,111
9,1117,8926,9248,40411,92211,2256,3928,42615,8774,63417,2186,27937,2706,44223,2523,09520,45619,94918,70113,7046,0591,2702,3572,4881,6806,396000000000
> Total Liabilities 
230,732
230,945
230,615
237,574
252,374
257,490
1,238,471
1,406,222
699,889
834,014
760,383
696,895
727,683
524,021
547,933
549,625
652,760
549,281
469,766
461,590
479,754
311,992
273,923
234,307
165,183
164,759
93,213
101,330
86,303
107,348
91,207
113,688
111,335
109,901
120,075
120,075109,901111,335113,68891,207107,34886,303101,33093,213164,759165,183234,307273,923311,992479,754461,590469,766549,281652,760549,625547,933524,021727,683696,895760,383834,014699,8891,406,2221,238,471257,490252,374237,574230,615230,945230,732
   > Total Current Liabilities 
227,129
226,995
225,840
231,683
238,868
246,979
632,850
793,344
82,249
186,777
108,985
35,695
17,002
20,438
29,264
42,300
100,111
95,805
52,497
36,297
41,665
42,578
167,853
135,241
98,810
98,929
29,388
15,727
16,782
17,818
18,565
24,772
37,112
58,683
64,734
64,73458,68337,11224,77218,56517,81816,78215,72729,38898,92998,810135,241167,85342,57841,66536,29752,49795,805100,11142,30029,26420,43817,00235,695108,985186,77782,249793,344632,850246,979238,868231,683225,840226,995227,129
       Short-term Debt 
212,910
215,748
218,630
221,557
224,529
227,547
210,370
213,144
26,433
26,756
27,087
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000027,08726,75626,433213,144210,370227,547224,529221,557218,630215,748212,910
       Short Long Term Debt 
212,910
215,748
218,630
221,557
224,529
227,547
210,370
213,144
26,433
26,756
27,087
0
0
0
0
0
0
0
0
0
0
0
114,974
76,600
76,695
76,790
0
0
0
0
0
0
0
0
0
00000000076,79076,69576,600114,9740000000000027,08726,75626,433213,144210,370227,547224,529221,557218,630215,748212,910
       Accounts payable 
9,131
11,136
1,799
3,617
2,259
3,407
2,682
1,647
4,183
5,061
2,888
2,040
2,420
3,365
6,103
10,169
3,784
9,469
17,273
7,233
8,403
6,972
19,153
15,887
5,307
6,135
9,582
2,475
2,427
1,893
1,793
4,694
5,233
5,366
8,584
8,5845,3665,2334,6941,7931,8932,4272,4759,5826,1355,30715,88719,1536,9728,4037,23317,2739,4693,78410,1696,1033,3652,4202,0402,8885,0614,1831,6472,6823,4072,2593,6171,79911,1369,131
       Other Current Liabilities 
5,088
111
86
1,161
4,876
7,620
410,486
569,286
41,729
23,384
19,076
1,794
7,773
8,124
13,232
20,468
72,239
69,832
24,402
15,710
18,763
19,584
18,380
22,779
412
67
14,212
916
256
127
146
128
206
26,993
37,157
37,15726,99320612814612725691614,2126741222,77918,38019,58418,76315,71024,40269,83272,23920,46813,2328,1247,7731,79419,07623,38441,729569,286410,4867,6204,8761,161861115,088
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
647,237
651,398
661,200
710,681
503,583
518,669
507,325
552,649
453,476
417,269
425,293
438,089
269,414
106,070
99,066
66,373
65,830
63,825
85,603
69,521
89,530
72,642
88,916
74,223
51,218
55,341
55,34151,21874,22388,91672,64289,53069,52185,60363,82565,83066,37399,066106,070269,414438,089425,293417,269453,476552,649507,325518,669503,583710,681661,200651,398647,237000000000
       Capital Lease Obligations 
0
0
0
0
0
0
0
0
0
1,187
11,478
10,858
11,212
10,714
10,909
4,949
12,236
7,610
2,320
13,693
15,540
18,660
2,551
37,286
11,051
11,886
11,671
6,329
6,165
6,194
7,583
7,357
7,105
4,448
5,742
5,7424,4487,1057,3577,5836,1946,1656,32911,67111,88611,05137,2862,55118,66015,54013,6932,3207,61012,2364,94910,90910,71411,21210,85811,4781,187000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
20,636
16,006
15,974
28,815
28,151
36,476
34,924
40,115
44,351
41,898
33,911
39,459
36,636
63,401
28,804
25,422
24,637
25,169
47,185
17,000
16,968
18,593
18,413
17,700
18,274
18,466
18,46618,27417,70018,41318,59316,96817,00047,18525,16924,63725,42228,80463,40136,63639,45933,91141,89844,35140,11534,92436,47628,15128,81515,97416,00620,636000000000
       Deferred Long Term Liability 
0
0
0
0
3,525
3,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000003,0003,5250000
> Total Stockholder Equity
341,290
371,830
409,409
424,763
418,647
497,178
619,813
699,520
560,914
1,079,974
1,041,453
850,581
767,232
661,896
695,003
697,824
709,525
745,840
786,517
812,066
821,629
793,192
802,365
816,298
597,485
646,317
664,892
667,896
700,913
806,521
775,198
841,178
830,439
795,534
828,529
828,529795,534830,439841,178775,198806,521700,913667,896664,892646,317597,485816,298802,365793,192821,629812,066786,517745,840709,525697,824695,003661,896767,232850,5811,041,4531,079,974560,914699,520619,813497,178418,647424,763409,409371,830341,290
   Common Stock
21
21
21
21
21
21
21
21
21
20
19
17
17
16
16
16
16
17
17
17
17
17
17
17
17
0
17
0
0
0
0
0
0
0
0
0000000017017171717171717171616161617171920212121212121212121
   Retained Earnings Total Equity00000000000000000000000000000000000
   Accumulated Other Comprehensive Income 00000000000000000000000000000000000
   Capital Surplus 00000000000000000000000000000000000
   Treasury Stock00000000000000000000000000000000000
   Other Stockholders Equity 
2,743
3,105
27,352
24,932
21,345
15,792
-151
-64
-1,024
-503
-542
-1,493
-216
-4,867
-2,310
-1,441
-801
-856
-861
-875
-917
-1,031
-1,066
-1,060
-984
0
-967
0
0
0
0
0
0
0
0
00000000-9670-984-1,060-1,066-1,031-917-875-861-856-801-1,441-2,310-4,867-216-1,493-542-503-1,024-64-15115,79221,34524,93227,3523,1052,743



6.4. Balance Sheets

Currency in USD. All numbers in thousands.




6.5. Cash Flows

Currency in USD. All numbers in thousands.




6.6. Income Statements

Currency in USD. All numbers in thousands.


6.7. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue167,133
Cost of Revenue-11,074
Gross Profit156,059156,059
 
Operating Income (+$)
Gross Profit156,059
Operating Expense-144,112
Operating Income23,02111,947
 
Operating Expense (+$)
Research Development21,425
Selling General Administrative78,654
Selling And Marketing Expenses-
Operating Expense144,112100,079
 
Net Interest Income (+$)
Interest Income8,055
Interest Expense-3,037
Other Finance Cost-0
Net Interest Income5,018
 
Pretax Income (+$)
Operating Income23,021
Net Interest Income5,018
Other Non-Operating Income Expenses-
Income Before Tax (EBT)2,51848,542
EBIT - interestExpense = -3,037
-4,032
-995
Interest Expense3,037
Earnings Before Interest and Taxes (EBIT)-5,555
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax2,518
Tax Provision-6,550
Net Income From Continuing Ops-4,032-4,032
Net Income-4,032
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-25,521-5,018
 

Technical Analysis of Ligand
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Ligand. The general trend of Ligand is BULLISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Ligand's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (100.0%) Bearish trend (-100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Ligand Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Ligand Pharmaceuticals Incorporated.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: .

The bearish price targets are: 158.00 > 151.00 > 151.00.

Know someone who trades $LGDN? Share this with them.πŸ‘‡

Ligand Pharmaceuticals Incorporated Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Ligand Pharmaceuticals Incorporated. The current mas is .

The long score for the Moving Averages is 14/14.
The longshort score for the Moving Averages is 14/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Ligand Pharmaceuticals Incorporated Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Ligand Pharmaceuticals Incorporated. The current macd is 4.30602758.

The long score for the Moving Average Convergence/Divergence (MACD) is 2/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 0/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Ligand price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Ligand. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Ligand price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Ligand Pharmaceuticals Incorporated Daily Moving Average Convergence/Divergence (MACD) ChartLigand Pharmaceuticals Incorporated Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Ligand Pharmaceuticals Incorporated. The current adx is 39.21.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Ligand shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
Ligand Pharmaceuticals Incorporated Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Ligand Pharmaceuticals Incorporated. The current sar is 152.07.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Ligand Pharmaceuticals Incorporated Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Ligand Pharmaceuticals Incorporated. The current rsi is 70.36. The current phase is Overbought in bull market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Overbought in bull market: Short-term excessive buying, potential for pullback. Consider taking profits, be cautious of potential correction. -1
  • Trending up: The RSI is trending up. +1
Ligand Pharmaceuticals Incorporated Daily Relative Strength Index (RSI) ChartLigand Pharmaceuticals Incorporated Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Ligand Pharmaceuticals Incorporated. The current phase is Overbought in bull market.

The long score for the Stochastic Oscillator is 6/6.
The longshort score for the Stochastic Oscillator is 6/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Ligand price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Ligand Pharmaceuticals Incorporated Daily Stochastic Oscillator ChartLigand Pharmaceuticals Incorporated Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Ligand Pharmaceuticals Incorporated. The current cci is 153.11.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Ligand Pharmaceuticals Incorporated Daily Commodity Channel Index (CCI) ChartLigand Pharmaceuticals Incorporated Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Ligand Pharmaceuticals Incorporated. The current cmo is 43.45.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Ligand Pharmaceuticals Incorporated Daily Chande Momentum Oscillator (CMO) ChartLigand Pharmaceuticals Incorporated Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Ligand Pharmaceuticals Incorporated. The current willr is -18.18181818.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Ligand Pharmaceuticals Incorporated Daily Williams %R ChartLigand Pharmaceuticals Incorporated Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Ligand Pharmaceuticals Incorporated.

Ligand Pharmaceuticals Incorporated Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Ligand Pharmaceuticals Incorporated. The current atr is 3.67013195.

Ligand Pharmaceuticals Incorporated Daily Average True Range (ATR) ChartLigand Pharmaceuticals Incorporated Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Ligand Pharmaceuticals Incorporated. The current obv is 2,603.

Ligand Pharmaceuticals Incorporated Daily On-Balance Volume (OBV) ChartLigand Pharmaceuticals Incorporated Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Ligand Pharmaceuticals Incorporated. The current mfi is 64.80.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Ligand Pharmaceuticals Incorporated Daily Money Flow Index (MFI) ChartLigand Pharmaceuticals Incorporated Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Ligand Pharmaceuticals Incorporated.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-06-13 00:00:00ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-16 00:00:00WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-17 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-18 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-19 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-20 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-25 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-26 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-27 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-06-30 00:00:00CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-07-03 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-07-04 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-08 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-09 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-11 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-07-15 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-16 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-17 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-18 00:00:00ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-21 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-25 00:00:00RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2025-07-28 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-30 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-31 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-01 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-08-06 00:00:00WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-08-07 00:00:00SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-08-08 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-08-11 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-08-12 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-08-14 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-19 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-08-20 00:00:00WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-08-22 00:00:00CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-08-25 00:00:00RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-27 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-08-28 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-29 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-09-01 00:00:00CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-09-02 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-05 00:00:00MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-09-08 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-09-09 00:00:00SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-09-11 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-09-15 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-16 00:00:00CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-09-17 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-09-19 00:00:00SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-09-23 00:00:00CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-09-25 00:00:00RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-29 00:00:00MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-09-30 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-10-01 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-10-02 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-10-03 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-10-06 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-10-08 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-10-09 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-10-13 00:00:00RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2025-10-14 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-10-15 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-10-16 00:00:00WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-10-17 00:00:00RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-10-21 00:00:00SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-10-23 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-10-24 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-10-27 00:00:00CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-10-28 00:00:00WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside

6.3. Candlestick Patterns

Ligand Pharmaceuticals Incorporated Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Ligand Pharmaceuticals Incorporated based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5070.361
Ma 20Greater thanMa 50154.000
Ma 50Greater thanMa 100144.400
Ma 100Greater thanMa 200126.045
OpenGreater thanClose162.000
Total5/5 (100.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Ligand with someone you think should read this too:
  • Are you bullish or bearish on Ligand? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Ligand? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Ligand Pharmaceuticals Incorporated

I send you an email if I find something interesting about Ligand Pharmaceuticals Incorporated.


Comments

How you think about this?

Leave a comment

Stay informed about Ligand Pharmaceuticals Incorporated.

Receive notifications about Ligand Pharmaceuticals Incorporated in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.